Zurueck zur Suche

Reporte zur Charge U020240

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

6Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
NC 1 MN 1 MD 1 MI 1 DE 1

VAERS 2296366

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U020240

mild
Staat
NC
Alter
22,0
Geschlecht
F
Eingang
26.05.2022
Impfdatum
19.04.2022
Beginn
03.05.2022
Tage bis Beginn
14,0
Dosis
2
Route/Site
SC / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Injection site rash Pyrexia Rash

Symptomtext

Pt reports she developed a rash and a fever (2 days with Tylenol use) 2-3 weeks after she received the varicella vaccine. She reports the rash started in the area she received the varicella vaccine and spread to her scalp but has improved since then. She denies experiencing and red flag symptoms such as SOB or difficulty breathing.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site rash
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2290188

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U020240

mild
Staat
MN
Alter
5,0
Geschlecht
F
Eingang
22.05.2022
Impfdatum
04.05.2022
Beginn
13.05.2022
Tage bis Beginn
9,0
Dosis
UNK
Route/Site
SC / LL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Vaccination site discolouration Vaccination site pain Vaccination site swelling

Symptomtext

The swollen area at the vaccine site was a golf ball-sized on 5.14.22, pink, slightly raised, and tender to touch. Treatment was mupirocin, ibuprofen if needed for pain, outline swollen area to assess if worsening and return to the clinic if signs of worsening infection (fever or red streaks). The parent was also advised to start oral antibiotics if symptoms persisted or worsened in the next 24-48 hours.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Vaccination site pain
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
N/A
Vorgeschichte
N/A
Andere Medikamente
N/A
Allergien
N/A
Vorherige Impfungen
-

VAERS 2652401

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U020240

gering
Staat
-
Alter
-
Geschlecht
U
Eingang
04.07.2023
Impfdatum
30.06.2023
Beginn
30.06.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

HCP reports no signs or symptoms noted. HCP has no further AE information.; HCP called to report a dose of VARIVAX that expired on 6/28/2023 was administered on 6/30/2023. Sterile Diluent used was also expired as of 1/26/2023.; This spontaneous report was received from an other health professional and refers to a patient of unknown age and gender. No information on patient's medical history, current conditions and concomitant medications was provided. On 30-JUN-2023 the patient was vaccinated with expired dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot # U020240, which is valid lot number and expiration date was established as 28-JUN-2023, 0.5 milliliter for prophylaxis (dose number, route and site of administration were not provided). Other suspect therapies included expiered sterile diluent (STERILE DILUENT) lot # T022569 and expiration date 26-JAN-2023 for prophylaxis (expired product administered and no adverse event

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Prophylaxis
Vorgeschichte
-
Andere Medikamente
STERILE DILUENT, lot# T022569
Allergien
-
Vorherige Impfungen
-

VAERS 2624821

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U020240

gering
Staat
MD
Alter
1,0
Geschlecht
M
Eingang
02.05.2023
Impfdatum
02.05.2023
Beginn
02.05.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
- / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
No adverse event Wrong product administered

Symptomtext

No adverse reaction. Medical assistant gave Proquad instead of MMR

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
n/a
Aktuelle Erkrankungen
n/a
Vorgeschichte
Eczema
Andere Medikamente
None
Allergien
None
Vorherige Impfungen
-

VAERS 2472203

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U020240

gering
Staat
MI
Alter
-
Geschlecht
U
Eingang
07.10.2022
Impfdatum
-
Beginn
31.08.2022
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

No additional AE reported; VARIVAX was administered after a temperature excursion; This spontaneous report was received from an other health professional and refers to a patient of unknown gender and age. The patient's medical history, concurrent conditions were and concomitant therapies were not reported. On 31-AUG-2022, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, lot #U020240, expiration date: 28-JUN-2023 (both confirmed to be valid) administered for prophylaxis (strength, and route of administration were not provided) (product storage error). The vaccine underwent a temperature excursion of 5.7 degree Fahrenheit for 0 hours 30 minutes and 0 seconds. There was previous temperature excursion of 6 degree Fahrenheit up to 14 degree Fahrenheit (9.1 degree Fahrenheit) for 1 hour 6 minutes and 0 seconds . No additional adverse event reported (no adverse event), no further information provided.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2249772

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U020240

gering
Staat
DE
Alter
1,0
Geschlecht
M
Eingang
25.04.2022
Impfdatum
01.04.2022
Beginn
01.04.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration No adverse event

Symptomtext

No additional AE details; VARIVAX and PROQUAD were inadvertently concomitantly administered to a 12 month old patient; This spontaneous report was received from a nurse referring to a 12-month-old male patient. The patient's medical history, concurrent conditions, and previous drug reactions or allergies were unknown by the reporter. Concomitant therapies included sterile diluent. On 01-APR-2022, the patient was inadvertently concomitantly administered measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant human albumin (rha) (PROQUAD) 0.5 milliliters (mL) subcutaneously (lot number U029149 has been verified to be valid, expiration date reported and established as 16-MAR-2023), and varicella virus vaccine live (Oka/Merck) (VARIVAX) 0.5 milliliters (mL), once (route of administration was not reported; lot number U020240 has been verified to be valid, expiration date reported and established as 28-JUN-2023) (inappropriate schedule of product administration). Both vaccines were administered as prophylaxis. No additional adverse event reported (no adverse event).

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
STERILE DILUENT
Allergien
-
Vorherige Impfungen
-